FY2026 EPS Estimates for TSE:BHC Raised by Zacks Research

Bausch Health Companies Inc. (TSE:BHC) – Equities research analysts at Zacks Research lifted their FY2026 earnings estimates for shares of Bausch Health Companies in a report released on Wednesday, August 19th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $5.88 for the year, up from their prior estimate of $5.54. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q1 2027 earnings at $1.17 EPS and FY2028 earnings at $4.22 EPS.

Bausch Health Companies (TSE:BHC) last announced its quarterly earnings results on Wednesday, July 29th. The company reported C$1.79 earnings per share (EPS) for the quarter. The company had revenue of C$4.05 billion for the quarter. Bausch Health Companies had a negative net margin of 12.02% and a positive return on equity of 87.57%.

Separately, Jefferies Financial Group upgraded shares of Bausch Health Companies to a “hold” rating in a research report on Wednesday, July 22nd. Three investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Bausch Health Companies Price Performance

BHC stock opened at C$9.48 on Thursday. The stock has a market cap of C$3.55 billion, a price-to-earnings ratio of -3.22, a P/E/G ratio of 0.21 and a beta of 0.96. The company has a debt-to-equity ratio of -1,173.29, a current ratio of 1.44 and a quick ratio of 0.58. The company has a 50 day simple moving average of C$7.45 and a 200 day simple moving average of C$7.55. Bausch Health Companies has a 1 year low of C$6.10 and a 1 year high of C$11.08.

Bausch Health Companies Company Profile

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.